MSCs in AML diagnosis demonstrate higher VEGFA, CXCL12, PGE2, IDO1, IL-1β, IL-6, and IL-32, with reduced IL-10 compared to MSCs in AML relapse [116]. This evidence concerns the gene IL6 and acute myeloid leukemia.